CJC-1295 (no DAC / Mod GRF 1-29)

What Is CJC-1295 (no DAC)?

CJC-1295 without DAC — commonly sold as “Modified GRF 1-29” — is a synthetic, tetra-substituted analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH), engineered to resist enzymatic degradation while keeping a short duration of action. Unlike the DAC version, it lacks the Drug Affinity Complex that binds albumin, so it does not accumulate; it is used (as a research chemical) to amplify a natural, pulsatile GH release, often paired with a GHRP such as ipamorelin. It is not an approved supplement or medicine, and there is little direct human trial data on this specific “no-DAC” form.

Evidence

The published human pharmacology for the CJC-1295 series comes from the long-acting DAC version, which raised GH and IGF-1 for days after single subcutaneous doses in healthy adults ^{1Reference 1Teichman SL et al. · 2006RCTProlonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — randomised, placebo-controlledView study →}. The short-acting “no-DAC” / Mod GRF 1-29 variant relies on the same GHRH(1-29) backbone and the tetra-substitution that improves stability, but I did not find a dedicated, verifiable human clinical trial of the no-DAC form in this quick pass — so its human efficacy (and its assumed advantage of producing a more physiological GH pulse) should be treated as uncited / inferred from the DAC data and general GHRH pharmacology, not demonstrated.

Dosage & Safety

CJC-1295 (no DAC) is a research peptide — not an approved dietary supplement or drug for human therapeutic use — and this entry is informational only. No validated human dose is established for the no-DAC form; figures circulating in peptide communities are not from controlled trials and are not a personal recommendation, so none is given here. As a GHRH analog it raises GH/IGF-1 and could plausibly affect insulin sensitivity, fluid retention and joint symptoms; formal human interaction, contraindication, pregnancy and long-term-safety data are not established / not assessed in this pass. Toxicity is not yet characterised from a citable basis.

References

1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults — randomised, placebo-controlled. J Clin Endocrinol Metab. https://pubmed.ncbi.nlm.nih.gov/16352683/